These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 1279214)

  • 1. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
    Lepor H; Auerbach S; Puras-Baez A; Narayan P; Soloway M; Lowe F; Moon T; Leifer G; Madsen P
    J Urol; 1992 Nov; 148(5):1467-74. PubMed ID: 1279214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
    Mudiyala R; Ahmed A
    J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
    Lepor H; Laddu A
    Br J Urol; 1992 Nov; 70 Suppl 1():2-9. PubMed ID: 1281728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    Lepor H; Machi G
    Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group.
    Debruyne FM; Witjes WP; Fitzpatrick J; Kirby R; Kirk D; Prezioso D
    Eur Urol; 1996; 30(3):369-76. PubMed ID: 8931972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
    Lepor H
    Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
    Lloyd SN; Buckley JF; Chilton CP; Ibrahim I; Kaisary AV; Kirk D
    Br J Urol; 1992 Nov; 70 Suppl 1():17-21. PubMed ID: 1281727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
    Fabricius PG; Weizert P; Dunzendorfer U; Hannaford JM; Maurath C
    Prostate Suppl; 1990; 3():85-93. PubMed ID: 1689173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
    Lepor H; Meretyk S; Knapp-Maloney G
    J Urol; 1992 Jun; 147(6):1554-7. PubMed ID: 1375659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of terazosin for the treatment of symptomatic BPH.
    Lepor H; Henry D; Laddu AR
    Prostate; 1991; 18(4):345-55. PubMed ID: 1711689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
    Fabricius PG; Hannaford JM
    Br J Urol; 1992 Nov; 70 Suppl 1():10-6. PubMed ID: 1281726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.